Yarrow Bioscience (YARW) closed at $20.21 on October 20, 2026, up 1.2% from the previous close, on volume of 105,470 shares (30-day average 159,666).
Data as of October 20, 2026.
No headlines found.
Business Wire (Mon, 14-Sep 4:05 PM ET)
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Business Wire (Thu, 10-Sep 9:11 PM ET)
Yarrow Bioscience Announces Proposed Underwritten Public Offering
Business Wire (Thu, 10-Sep 4:03 PM ET)
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire (Thu, 13-Aug 7:00 AM ET)
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Yarrow Bioscience trades on the NASDAQ stock market under the symbol YARW.
As of October 21, 2026, YARW stock price declined to $20.13 with 886 million shares trading.
YARW has a market cap of $169.88 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that YARW belongs to (by Net Assets): VTI, VXF, DFAS, DFMC.
YARW support price is $18.89 and resistance is $21.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that YARW shares will trade within this expected range on the day.
